Back to Search
Start Over
AdvanTIG-202: A phase 2 study investigating anti-T cell immunoglobulin and ITIM domain monoclonal antibody ociperlimab plus tislelizumab in patients with previously treated recurrent or metastatic cervical cancer (333).
- Source :
-
Gynecologic Oncology . 2022 Supplement 1, Vol. 166, pS172-S172. 1p. - Publication Year :
- 2022
- Subjects :
- *MONOCLONAL antibodies
*CERVICAL cancer
*METASTASIS
Subjects
Details
- Language :
- English
- ISSN :
- 00908258
- Volume :
- 166
- Database :
- Academic Search Index
- Journal :
- Gynecologic Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 159029670
- Full Text :
- https://doi.org/10.1016/S0090-8258(22)01555-4